Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023)

Monte Rosa Therapeutics' Non Operating Investment Income history spans 1 years, with the latest figure at -$131000.0 for Q1 2023.

  • For Q1 2023, Non Operating Investment Income changed N/A year-over-year to -$131000.0; the TTM value through Dec 2023 reached -$131000.0, changed N/A, while the annual FY2023 figure was -$131000.0, N/A changed from the prior year.
  • Non Operating Investment Income reached -$131000.0 in Q1 2023 per GLUE's latest filing.
  • In the past five years, Non Operating Investment Income ranged from a high of -$131000.0 in Q1 2023 to a low of -$131000.0 in Q1 2023.